← back to database
The Longevity Fund's successor, age1, invests at the earliest stages in companies developing therapies and enabling technologies that extend healthy human lifespan. It prefers to lead and writes initial checks from $500,000 to $4 million, supporting companies from formation through seed and Series A.
Stage focus
Lead / follow
Check size
Ownership target
Specialization
Generalist / Specialist
Specialist
Investing team
Alex ColvilleCo-Founder and General Partner
Satvik DasarirajuPrincipal
How to reach them
Notable investments
Unity Biotechnology, ALX Oncology, NewLimit, Fauna Bio, Precision BioSciences